Life Sciences Advisory and Strategic Investment Banking Solutions

Even if there is an interesting scientific project, its financing may be challenging, as there is a tendency for companies to start their planning too late in terms of financial aspects. Today, the discussion on capital raising in the life sciences industry is linked to the company's corporate strategy. Therefore, there is a great need for strategic investment banking solutions. Life sciences businesses develop for a very long time. Therefore, research programs, development and commercialization of products require a lot of money well before any income is generated. In such situations, it is hard to choose between financing options. However, the problem is not only in finding the money, as the timing is crucial. Companies need to evaluate their development priorities, partnerships and other things at the same time. It is necessary to pay attention to these questions as one of the decisions can have an impact on others. As the situation requires the analysis of many aspects, the management of companies asks for help from advisory and strategic investment banking specialists before making decisions. This way, it is easier to understand what ways are possible in advance. It means that there is a need to find a solution that would help to consider all questions before approaching the investors or making transactions. As a result, it is becoming harder to raise the funds due to the complexity of the question. In addition, it is important to understand that investors also think not only about the financing of the company but also about other factors. It is crucial to think about the business direction, development goals and positioning of the company. It is clear that companies that have a plan for financing will be ready to answer the questions of the investors. Advisory specialists became more popular as leaders face difficult decisions that should take into account not only finances but also the transaction timing and priorities of the company. These decisions can affect future plans for the development of the company. In such situations, external specialists are needed. Life sciences companies are small and do not have enough specialists who can deal with such issues. Therefore, advisory services become part of the process. It is obvious that today the demand for advisory and investment banking services in life sciences is related not only to transactions but also to planning. Companies need help in their planning as the situation becomes more complicated. Thus, capital raising becomes an integral part of the planning process of the life sciences businesses. It becomes clear that financing discussions should be made not in isolation but in context with the corporate objectives. In the future, the demand for such advice will probably continue to grow.

A life sciences company does not necessarily have to consider independent growth for its future prospects. The issues of collaborating or entering into license agreements and other partnership arrangements are among the aspects that can gain significance during the process. That is how the demands for advice in connection with transactions involving life sciences are changing. Companies are increasingly looking at the possibility of partnerships in conjunction with conventional financing matters, which creates a new opportunity for transaction advisory services providers. Partnering decisions can affect the future of a company over a period of years. Possibility to obtain additional expertise or reach of markets can be the reason for making such a decision, and these aspects usually require taking into account various factors beyond finance. Management teams usually ask for assistance with the evaluation of the potential alternatives even before the negotiations begin. This allows determining whether a certain partnership can be beneficial for the future of the company and what implications will be created by different transaction models. The complexity of these decisions makes them especially important. A partnering agreement will have an impact on the way the resources are used and the development priorities of a company, so this issue requires proper consultation before negotiating with a counterparty. Such consulting needs arise in life sciences companies due to the specificity of the industry – scientific programs usually require special expertise and significant investments. In this case, collaboration with another company can give access to this expertise. Advisory firms providing investment banking solutions are increasingly involved in such discussions. Their role involves analysis of transaction structures, their implications from the strategic point of view, and assistance in comparing different scenarios offered to the management team. The increased attention paid to the partnership is caused by changes in the whole life sciences sector. Companies are no longer following the same strategies concerning growth; sometimes, collaboration can be the only possible alternative for a certain situation. The decision-making process becomes especially complicated when several different opportunities occur at the same time. Managers have to weigh different financing alternatives and partnering proposals in light of the strategic goals of their companies. All this contributes to the emergence of demand for advisory services that go beyond capital raising. The companies usually want to have a structured assessment of the strategic alternatives before making any decision. The increased significance of partnership discussions means that transaction advisory services in life sciences have become more diverse. Strategic aspects of collaborations are now given much attention along with the usual financial considerations. In the future, activities in the field will likely reflect this trend.

Transactions that seem interesting during their initial phases are not uncommon. In life sciences financing events, partnerships and other strategic transactions, transaction execution risk remains a major consideration. The above issue is fueling the growth of the advisory and strategic investment banking services in the industry. The businesses understand that, besides finding opportunities, the ability to manage transactions is crucial in achieving success. Most of the life sciences transactions require a lot of preparatory work. Information collection, due diligence activities, and stakeholder communication may be time-consuming tasks that may slow down a transaction. Most of the time, the companies enter into the process while being responsible for other things. Managing the research projects and conducting the business activities at the same time can cause problems. Advisors are usually employed to manage the above issue. The involvement of advisors may include coordination of transaction workflow, creating necessary documents and managing procedural requirements during negotiations. Transaction execution risk is an especially significant problem in life sciences due to the specific nature of the transactions. Potential investors or partners may need comprehensive information before starting any activity. Preparation of such information is not an easy task. Transaction execution is a more complicated process than document preparation. Scheduling may have an effect on transaction execution. Problems in one phase of the process can change the schedule of all the participants. Companies that decide to choose an advisor pay attention not only to the strategic skills of an advisor but also his/her ability to manage transactions. Finding new opportunities is a critical aspect, but transaction management has become an essential value-added service. The above problem is caused by the specific situation on the market. Most of the companies realize that transaction complexity increases when the transaction process starts officially. Proper coordination can help to decrease the friction in negotiations. In response to the demand of the customers, the life sciences advisory and investment banking firms are increasing the emphasis on process management. Often, clients ask for help with the transaction process. As can be seen from the above discussion, transaction execution risk shows a very important aspect of the market. It is clear that despite the strategic opportunities and interests, the ability to manage a process is crucial. Transaction execution will remain an important aspect of future advisory engagement. Companies interested in significant transactions will value the ability of the advisor to deal with the execution risks.